However, this method has problems such as high staining costs, tumor heterogeneity, and subjective differences among pathologists. Therefore, the application of deep learning models to segment and ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

The proinflammatory cytokine interleukin 6 (IL-6) is highly elevated in patients with pancreatic cancer and is a prognostic factor for outcome. Pancreatic stellate cells are a major source of IL-6 in ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

An international team of UK and US scientists discovered that the activity of macrophages -- a type of white blood cell that engulf pathogens and cancer cells -- can be used to predict whether or not ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in ...

Tecentriq, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50 ...

The Phase 1/2a clinical trial enrolled patients with advanced, refractory cancers unresponsive to prior anti-PD-1 or anti-PD-L1 therapies ... sequential tumor biopsies and immune cell analysis.